Increasing Transparency in Generic Drug Applications Act

[AI summary unavailable — showing source text] [Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 1302 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S. 1302 To provide for increased transparency in generic drug applications. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES April 3, 2025 Ms. Hassan (for herself, Mr. Paul, Mr. Hickenlooper, and Mr. Lee) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To provide for increased transparency in generic drug applications. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Increasing Transparency in Generic Drug Applications Act''. SEC. 2. INCREASING TRANSPARENCY IN GENERIC DRUG APPLICATIONS. (a) In General.--Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is amended by adding at the end the following: ``(H)(i) Upon request (in controlled correspondence or an analogous proc…